Standout Papers

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System 2022 2026 2023 2024105
  1. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System (2022)
    Scott Dryden‐Peterson, Andy Kim et al. Annals of Internal Medicine

Immediate Impact

32 standout
Sub-graph 1 of 11

Citing Papers

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
2024 Standout
Mechanisms of long COVID and the path toward therapeutics
2024 Standout
3 intermediate papers

Works of Andy Kim being referenced

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System
2022 Standout

Author Peers

Author Last Decade Papers Cites
Andy Kim 116 65 30 41 24 236
Mirela Loredana Grigoraş 85 54 35 45 38 282
Rakesh D. Mistry 54 49 29 11 19 189
Waleed Aletreby 96 113 28 45 24 244
Mahmoud Sadeghi Haddad Zavareh 153 82 23 37 23 211
Irawaty Djaharuddin 102 46 30 50 35 206
Zbigniew Król 85 67 12 13 25 167
Salah Eddine Oussama Kacimi 103 59 22 48 18 266
Marie Charmaine C. Sy 92 127 24 30 21 210
Ankita Pandey 120 55 14 33 22 243
Anu Anna George 134 61 49 72 33 277

All Works

Loading papers...

Rankless by CCL
2026